ZyVersa Therapeutics, Inc. – NASDAQ:ZVSA
ZyVersa Therapeutics stock price today
ZyVersa Therapeutics stock price monthly change
ZyVersa Therapeutics stock price quarterly change
ZyVersa Therapeutics stock price yearly change
ZyVersa Therapeutics key metrics
Market Cap | 2.88M |
Enterprise value | 13.66M |
P/E | -0.79 |
EV/Sales | N/A |
EV/EBITDA | -7.28 |
Price/Sales | N/A |
Price/Book | 137.13 |
PEG ratio | N/A |
EPS | -165 |
Revenue | N/A |
EBITDA | 68.53M |
Income | -97.58M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeZyVersa Therapeutics stock price history
ZyVersa Therapeutics stock forecast
ZyVersa Therapeutics financial statements
| Jun 2023 | 0 | -78.51M | |
|---|---|---|---|
| Sep 2023 | 0 | -2.90M | |
| Dec 2023 | 15.6K | -13.33M | -85503.21% |
| Mar 2024 | 0 | -2.82M |
| 2025 | 0 | -28.14M | |
|---|---|---|---|
| 2026 | 0 | -39.59M | |
| 2027 | 0 | -8.67M | |
| 2028 | 35M | -10.90M | -31.15% |
Analysts Price target
Financials & Ratios estimates
| 2023-11-14 | -5.59 | -3.15 |
|---|
| Jun 2023 | 31987793 | 11.92M | 37.28% |
|---|---|---|---|
| Sep 2023 | 32852009 | 13.14M | 40.02% |
| Dec 2023 | 22114284 | 11.03M | 49.92% |
| Mar 2024 | 21650764 | 10.42M | 48.16% |
| Jun 2023 | -407.62K | 0 | -641.76K |
|---|---|---|---|
| Sep 2023 | -936.39K | 0 | 2.28M |
| Dec 2023 | -2.78M | 0 | 4.34M |
| Mar 2024 | -3.77M | 0 | 2.67M |
ZyVersa Therapeutics alternative data
| Aug 2023 | 7 |
|---|---|
| Sep 2023 | 7 |
| Oct 2023 | 7 |
| Nov 2023 | 7 |
| Dec 2023 | 7 |
| Jan 2024 | 7 |
| Feb 2024 | 7 |
| Mar 2024 | 7 |
| Apr 2024 | 7 |
| May 2024 | 7 |
| Jun 2024 | 7 |
| Jul 2024 | 7 |
ZyVersa Therapeutics other data
-
What's the price of ZyVersa Therapeutics stock today?
One share of ZyVersa Therapeutics stock can currently be purchased for approximately $0.15.
-
When is ZyVersa Therapeutics's next earnings date?
Unfortunately, ZyVersa Therapeutics's (ZVSA) next earnings date is currently unknown.
-
Does ZyVersa Therapeutics pay dividends?
No, ZyVersa Therapeutics does not pay dividends.
-
How much money does ZyVersa Therapeutics make?
ZyVersa Therapeutics has a market capitalization of 2.88M. ZyVersa Therapeutics made a loss 98.3M US dollars in net income (profit) last year or -$3.15 on an earnings per share basis.
-
What is ZyVersa Therapeutics's stock symbol?
ZyVersa Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ZVSA".
-
What is ZyVersa Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ZyVersa Therapeutics?
Shares of ZyVersa Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does ZyVersa Therapeutics have?
As Jul 2024, ZyVersa Therapeutics employs 7 workers.
-
When ZyVersa Therapeutics went public?
ZyVersa Therapeutics, Inc. is publicly traded company for more then 3 years since IPO on 11 Feb 2022.
-
What is ZyVersa Therapeutics's official website?
The official website for ZyVersa Therapeutics is zyversa.com.
-
Where are ZyVersa Therapeutics's headquarters?
ZyVersa Therapeutics is headquartered at 2200 N. Commerce Parkway, Weston, FL.
-
How can i contact ZyVersa Therapeutics?
ZyVersa Therapeutics's mailing address is 2200 N. Commerce Parkway, Weston, FL and company can be reached via phone at +7 542311688.
ZyVersa Therapeutics company profile:
ZyVersa Therapeutics, Inc.
zyversa.comNASDAQ
7
Biotechnology
Healthcare
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
Weston, FL 33326
CIK: 0001859007
ISIN: US98987D2018
:
